Cargando…
Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) comprises about 85% of all lung cancers. Currently, NSCLC therapy is based on the analysis of specific predictors, whose presence qualifies patients for appropriate treatment. Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5), also known as “survivin”,...
Autores principales: | Szczyrek, Michał, Mlak, Radosław, Szudy-Szczyrek, Aneta, Wojas-Krawczyk, Kamila, Kędziora, Karolina, Milanowski, Janusz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946487/ https://www.ncbi.nlm.nih.gov/pubmed/35326407 http://dx.doi.org/10.3390/cells11060956 |
Ejemplares similares
-
Polymorphisms in the Gene Encoding Caspase 8 May Predict the Response to First-Line Platinum-Based Chemotherapy in Locally Advanced or Advanced Non-Small-Cell Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2021) -
Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2016) -
The impact of ACE gene polymorphism on the incidence and phenotype of sarcoidosis in rural and urban settings
por: Kieszko, Robert, et al.
Publicado: (2015) -
Methylation of DROSHA and DICER as a Biomarker for the Detection of Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2021) -
Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2018)